You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Systemic Therapy of Incurable Gastroenteropancreatic Neuroendocrine Tumours

ID: GL 2-21 Dec 2016
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
S. Singh, D. Sivajohanathan, T. Asmis, C. Cho, N. Hammad, C. Law, R. Wong, K. Zbuk, Gastrointestinal Disease Site Group

Guideline Objective

To make recommendations with respect to systemic therapy for the treatment of patients with incurable gastroenteropancreatic (GEP) neuroendocrine tumours (NETs).

Patient Population

Adults with a diagnosis of incurable GEP NETs.

Intended Guideline Users

Clinicians involved in the treatment of patients with GEP NETs.

Research Questions

Which of the anti-neoplastic systemic therapies (i.e., chemotherapy, SSAs and interferon α, and targeted therapies [i.e., sunitinib, everolimus, bevacizumab, pazopanib]) is the most effective in improving clinical outcomes (i.e., PFS, OS, ORR, median survival, symptom control, biomarker decreases, quality of life) while minimizing adverse effects (i.e., toxicity) in patients with incurable GEP NETs?

pdf download Summary (PDF) (153.21 KB)